Welcome to our dedicated page for Relay Therapeutics SEC filings (Ticker: RLAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Relay Therapeutics, Inc. (Nasdaq: RLAY) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. As a clinical-stage precision medicine company focused on small molecule therapies for cancer and genetic disease, Relay Therapeutics uses these filings to report on its financial condition, governance and material developments related to programs such as its PI3Kα inhibitor RLY-2608, also known as zovegalisib.
Among the most frequently referenced documents are current reports on Form 8-K, which Relay Therapeutics files to announce events such as quarterly financial results and changes to its Board of Directors. For example, 8-K filings describe the release of earnings press statements for specific quarters and the appointment of new independent directors, along with related committee assignments and equity compensation terms.
Investors researching RLAY can also use this page to locate periodic reports such as Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, which the company cites in its risk factor discussions within press releases. These filings typically contain detailed information on research and development expenses, general and administrative costs, net losses, and risk factors associated with developing clinical-stage programs like RLY-2608 and other pipeline assets.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand topics such as results of operations, liquidity, and governance changes. Real-time updates from the EDGAR system ensure that new Relay Therapeutics filings, including future Forms 10-K, 10-Q, 8-K and beneficial ownership or insider transaction reports like Form 4, appear promptly on this page.
By combining the raw SEC documents with AI-generated overviews, this filings page offers a structured view into Relay Therapeutics’ regulatory history, financial reporting and significant corporate events relevant to the RLAY stock.
Relay Therapeutics reported early clinical data for its PI3Kα inhibitor zovegalisib in a triplet regimen with atirmociclib and fulvestrant in heavily pre‑treated HR+/HER2‑ metastatic breast cancer. Among 34 patients with measurable disease, the objective response rate was 44% (15/34), similar in kinase and non‑kinase PIK3CA mutations, and 85% showed tumor shrinkage.
Safety in 62 treated patients appeared manageable: only 3% discontinued and 10% dose‑reduced zovegalisib for treatment‑related adverse events, with a 40% grade 3+ TRAE rate primarily due to neutropenia and no febrile neutropenia. As of the April 13, 2026 data cut‑off, 77% (48/62) of patients remained on study with a median follow‑up of 7.4 months, and median progression‑free survival has not yet been reached.
Based on these data, Relay plans, subject to regulatory feedback, a randomized Phase 3 frontline trial in endocrine‑sensitive, PIK3CA‑mutated HR+/HER2‑ advanced or metastatic breast cancer, testing zovegalisib plus atirmociclib and an aromatase inhibitor versus an investigator’s‑choice CDK4/6 inhibitor plus aromatase inhibitor. Pfizer will supply atirmociclib and palbociclib, while Relay sponsors and funds the trial.
Relay Therapeutics, Inc. is soliciting proxies for its 2026 Annual Meeting of Stockholders to be held virtually on June 9, 2026 at 3:00 p.m. Eastern Time. The meeting agenda includes election of two Class III directors, an advisory vote on executive compensation, ratification of Ernst & Young LLP as auditor, and a proposal to amend the certificate of incorporation to increase authorized common shares from 300,000,000 to 450,000,000.
Stockholders of record as of April 13, 2026 may vote; proxy materials and the 2025 Annual Report will be made available starting on or about April 29, 2026. The board recommends a vote FOR all proposals. Registration for the virtual meeting is required by June 5, 2026 at 5:00 p.m. ET via www.proxydocs.com/RLAY.
Kiora Pharmaceuticals reported that Perceptive Life Sciences Master Fund, Ltd. directly holds 438,471 shares of Common Stock, representing 9.99% of the class. Perceptive Advisors LLC and Joseph Edelman are each reported as beneficial owners of the same 438,471 shares (9.99%) through shared voting and dispositive power. The filing ties the outstanding share base to 4,389,099 shares, comprised of 3,950,628 shares outstanding as of March 21, 2026 and 438,471 shares issued in a private placement on April 6, 2026.
Relay Therapeutics, Inc. Chief Financial Officer Thomas Catinazzo reported option exercises and share sales. On April 9, 2026, he exercised a stock option to acquire 1,800 shares of common stock at $5.22 per share and then sold 1,800 shares at $15.00 per share.
On April 7, 2026, he sold an additional 17,717 shares of common stock at a weighted average price of $13.01 per share, with trades executed between $12.42 and $13.46. The filing states these transactions were made under a Rule 10b5-1 trading plan. After these transactions, he directly owns 213,867 shares, including 13,075 shares underlying restricted stock units.
The Vanguard Group filed Amendment No. 5 to a Schedule 13G/A reporting beneficial ownership in Relay Therapeutics Inc Common Stock. The filing states that, following an internal realignment effective January 12, 2026, the reporting entities disaggregated holdings and report beneficial ownership of 0 shares (0%) for this class. The filing lists Vanguard's address and explains that certain subsidiaries now report separately in reliance on SEC Release No. 34-39538. The form is signed by Ashley Grim as Head of Global Fund Administration on March 27, 2026.
Relay Therapeutics reports that Perceptive Life Sciences Master Fund, Perceptive Advisors LLC and Joseph Edelman each beneficially own 9,404,725 shares of Common Stock, representing 5.3% of the class.
Ownership is shown as shared voting and dispositive power for 9,404,725 shares. The filing cites 178,725,809 shares outstanding as of February 20, 2026 as the basis for percentage calculation.
Relay Therapeutics reported new Phase 1/2 data for its PI3Kα inhibitor zovegalisib combined with fulvestrant at the recommended Phase 3 dose of 400mg twice daily with food in PI3Kα‑mutated, HR+/HER2- metastatic breast cancer.
Among 57 efficacy-evaluable patients as of the January 13, 2026 cut-off, median progression-free survival was 11.1 months, with similar outcomes for kinase and non‑kinase mutations. In 35 patients with measurable disease, the confirmed objective response rate was 43%, and 52% in second-line-only patients. The regimen was generally well tolerated in 60 treated patients, with mostly low‑grade, manageable adverse events, a hyperglycemia profile dominated by Grade 1 events, and only four discontinuations due to treatment-related side effects. These data support use of the 400mg fed dose in the ongoing global Phase 3 ReDiscover‑2 trial, for which the combination has FDA Breakthrough Therapy designation.
Relay Therapeutics, Inc. Chief Financial Officer Thomas Catinazzo reported an open-market sale of 17,717 shares of common stock on March 9, 2026 at a weighted average price of $10.06 per share. The trades were executed at prices ranging from $9.77 to $10.35 pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on October 30, 2025. Following this transaction, he directly holds 231,584 shares of Relay Therapeutics common stock, which include 13,075 shares underlying restricted stock units.
Relay Therapeutics, Inc. updated its corporate bylaws to change where certain securities-related lawsuits can be filed. On March 6, 2026, the Board approved second amended and restated bylaws that designate the federal district courts of the United States as the exclusive forum for complaints asserting causes of action under the Securities Act of 1933, the Securities Exchange Act of 1934, or related rules and regulations, unless the company consents in writing to a different forum.
Thomas J. Catinazzo reported sales of company common stock. The filing lists two dispositions: 13,820 shares for $105,308.40 on 01/27/2026 and 1,695 shares for $14,322.75 on 01/28/2026. The record also lists Restricted Stock Units dated 01/27/2025 as securities to be sold.